Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect on Radotinib PK in Healthy Adults
NCT06461078Phase 1Completed
- Sponsor
- Il-Yang Pharmaceutical
- Start
- Jul 2024
- Primary completion
- Sep 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of radotinib in chronic myeloid leukemia (CML) (2 arms), sponsored by Il-Yang Pharmaceutical. Primary endpoints: Maximum concentration of drug in plasma and Area under the plasma drug concentration-time curve to last concentration. Started Jul 2024; status: completed.
02
Drugs
radotinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT06461078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06461078.